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Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor
Degeneration in a Mouse Model of Leber Congenital Amaurosis
Wei Zhang,1 Linjing Li,1 Qin Su,2 Guangping Gao,2 and Hemant Khanna1,2,*
1Department of Ophthalmology and 2Horae Gene Therapy Center, UMASS Medical School, Worcester, Massachusetts.
Mutations in the cilia-centrosomal protein CEP290 are frequently observed in autosomal recessive
childhood blindness disorder Leber congenital amaurosis (LCA). No treatment or cure currently exists for
this disorder. The Cep290rd16 (retinal degeneration 16) mouse (a model of LCA) carries a mutation in the
Cep290 gene. This mutation leads to shorter cilia formation and defective photoreceptor structure and
function. A roadblock to developing a gene replacement strategy for CEP290 using conventional adeno-
associated virus (AAV) vectors is its large size. The identification and characterization is reported of a
miniCEP290 gene that is amenable to AAV2/8-mediated delivery and delaying retinal degeneration in the
Cep290rd16 mice. Using the ability of Cep290rd16 mouse embryonic fibroblasts to from shorter cilia as a
platform, a human CEP290 domain encoded by amino acids 580–1180 (miniCEP290580-1180) was identified
that can recover the cilia length in vitro. Furthermore, subretinal injection of AAV particles carrying the
cDNA expressing miniCEP290580-1180 into neonatal Cep290rd16 mice resulted in significantly improved
photoreceptor survival, morphology, and function compared to control injected mice. These studies show
the potential of using a truncated CEP290 to treat this fast progressing and devastating disease.
Keywords: cilia, retina, photoreceptor, ciliopathies, gene therapy, LCA
INTRODUCTION
THE CILIUM IS AN EVOLUTIONARILY conserved sen-
sory organelle involved in regulating development
and homeostasis.1 In the light-sensing neurons
called photoreceptors (PRs), the bridge-like ‘‘con-
necting cilium’’ links the light-sensing outer
segment to the protein-synthesizing inner seg-
ment.2 Mutations in the genes encoding ciliary
proteins result in disorders collectively termed
‘‘ciliopathies’’ that can affect the retina alone or as
part of a syndromic disease.3 One of the most se-
vere forms of retinal ciliopathies is Leber con-
genital amaurosis (LCA).4 This disorder results
in early and profound PR dysfunction and de-
generation, usually beginning at birth or by
around 5 years of age. CEP290mutations are also
associated with syndromic ciliopathies, includ-
ing Joubert syndrome, Meckel–Gruber Syndrome,
Bardet–Biedl syndrome (BBS), and Senior–Løken
syndrome.5–10 No treatment or cure currently exists
for such diseases.4
Mutations in the cilia-centrosomal protein encod-
ing gene CEP290 are the most frequent cause of
LCA, accounting for >25% of LCA (LCA10; OMIM
611755).11 It has been demonstrated that CEP290 is
involved in regulating the cilia assembly program.
Mouse embryonic fibroblasts (MEFs) derived from a
Cep290-mutant (Cep290rd16) mouse model of LCA-
like PR degeneration12 have fewer ciliated cells and
formshortercilia.13Moreover, theCEP290-associated
disease is likely due to reduction or the loss of normal
protein function.6,14–16 Although antisense oligonu-
cleotides and genome editing have been used to cor-
rect a common intronic mutation in CEP290, both
aremutation-dependent approaches.17–20 Lentivirus-
mediated delivery of the full-length (FL) CEP290
into patient-derived fibroblasts was also shown to
rescue the CEP290-associated defect in vitro.13
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However, its efficacy and long-term safety have not
been demonstrated in vivo.
Recent studies have reported the development
and characterization of several vertebrate models
of Cep290. Mice generated either using gene trap
alleles or by creating a null allelewithin exons 1–4 or
exons 36–37 of mouse Cep290 recapitulate the phe-
notypes associated with syndromic ciliopathies.21–23
However, they are not ideal model systems to in-
vestigate nonsyndromic LCA due to CEP290 muta-
tions. Earlier studies also identified a naturally
occurring felinemodel of retinal degeneration due to
CEP290 mutation in exon 50. As predicted, this
model undergoes relatively delayed and late onset
form of retinal degeneration.24
The identification and characterization of a nat-
urally occurring mouse mutant of Cep290, termed
Cep290rd16, was previously reported.12 This mutant
carries an in-frame deletion within exons 37–41 of
mouse Cep290, which encodes a part of the myosin-
tail homology domain (deleted aa 1606–1904). The
deletion results in the production of a truncated
CEP290 variant, which is partially functional. The
Cep290rd16 mouse exhibits non-syndromic retinal
degeneration, which mimics the LCA onset and
phenotype observed in patients.12,25 Moreover, the
regionof thehumanCEP290gene that ishomologous
to the domain deleted in the Cep290rd16 mouse har-
bors LCA-causing mutations. Thus, the Cep290rd16
mice provide an excellent platform to initiate thera-
peutic investigations.
Adeno-associated virus (AAV) vector-mediated
delivery of the transgene into the subretinal space is
a safe and effective approach to treat PR degenera-
tive diseases.26–30 However, a roadblock in AAV-
mediatedCEP290 delivery is the size of theCEP290
cDNA (*8kb), which exceeds the transgene pack-
aging capacity of the conventional AAV vectors
(*4.0kb).31 This study was undertaken to engineer
AAV-amenable miniCEP290 genes encoding func-
tionally optimized proteins, as described previously
for muscular dystrophy causing gene dystrophin.32
The studies provide evidence for the suitability of
using miniCEP290 as a readily translatable para-
digm for CEP290-LCA.
MATERIALS AND METHODS
Plasmid constructs and AAV production
For in vitro experiments, FL or miniCEP290-
expressing cDNAs were cloned into a pEGFP-C1
plasmid expressingGFP-tagged proteins under the
control of a CMV promoter. For AAV production,
the miniCEP290-encoding cDNAs were cloned into
a pAAV2 vector plasmid between a CMVenhancer/
CBA (chicken b-actin) promoter upstream of the
internal ribosome entry site (IRES) GFP and b-
globin intron. This expression cassette was flanked
with AAV2 inverted terminal repeats (ITRs). The
recombinant AAV2 genomes were packaged with
AAV8 capsid by HEK293-triple transfection method
andpurified byCsCl gradient centrifugationmethod,
as previously described.33
Cell culture, transient transfection,
and immunostaining
MEFsderived fromwild-type (WT) andCep290rd16
mice were maintained in Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum. Tran-
sient transfection with GFP-CEP290-FL or GFP-
miniCEP290s was performed using Lipofectamine
2000 (Thermo Fisher). The transfected cells were
either harvested for immunoblotting or were serum
starved to induce cilia growth, as described.34 The
ciliated cells were then immunostained and imaged
under a Leica microscope (DM5500). The cilia
length was measured by using Image J. The pixel
values of cilia length were transformed into actual
length using the Leica Application Suite. The rela-
tionship between pixel length and actual length at
63·magnification is: 680 pixels=100lm.
Subretinal injection
All animal studies were approved by the In-
stitutional Animal Care and Use Committee of the
UMASS Medical School. The WT C57BL6/J mice
were obtained from Jackson Laboratories. The
Cep290rd16 mice have been described previously.12
The Cep290rd16 mouse pups (P0/P1) were sub-
retinally injected unilaterally with 8 ·109 vg/lL
(total volume 1lL) of the virus.35,36
Electroretinogram and immunofluorescence
microscopy of the retina
Scotopic and photopic electroretinograms (ERGs)
were performed, as previously reported.37 For sco-
topic response, mice were dark adapted overnight,
and all procedures were performed under dim red
light. The dark-adapted ERG protocol consisted of
five steps with increasing stimulus intensities from
0.009 to 100 cd.s/m2, with amixedwhite light (white
6,500K; ColorDome; Diagnosys LLC). The flash
frequency was 0.07Hz for bright flashes and up to
0.5Hz for dim flashes. Averages ranged from 10
trials for dim flashes to five trials for bright flashes.
Light-adapted (photopic) ERGs were recorded after
light adaptation with a background illumination of
30 cd/m2 (white 6,500K) for 8min.
Immunofluorescence microscopy was performed
essentially as described.37 In brief, retinal cryosec-
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tions were stained with primary antibodies: rho-
dopsin (mousemonoclonal; EMDMillipore),M-opsin
(rabbit polyclonal; EMD Millipore), and peripherin-
retinal degeneration slow (RDS; mouse monoclonal;
gift from Dr. Muna Naash), ARL13B (rabbit poly-
clonal; Abcam), GFP (chicken polyclonal; Abcam),
and c-tubulin (mouse monoclonal; Sigma–Aldrich).
Afterwashingwithphosphate-bufferedsaline,Alexa-
488 or Alexa-546 or Alexa-633-conjugated secondary
antibodies were added, and the sections were further
incubated for 1h. After washing, nuclei were stained
with DAPI, and cells were imaged using a Leica mi-
croscope (DM5500).
Statistical analysis
All data are presented asmeans– standard error
of the mean. Data groups were compared by Stu-
dent’s t-tests using the SigmaPlot software. Differ-
ences between groups were considered statistically
significant if p<0.05. The statistical significance is
denoted with asterisks (*p<0.01–0.05; **p<0.001–
0.01; ***p<0.0001–0.001).
RESULTS
Construction and in vitro functional
potential of miniCEP290s
The human CEP290 gene consists of 52 exons,
which encode a protein of *290kDa (2,479 amino
acids). Based on the previous studies on the involve-
ment of the different CEP290 domains in its inter-
actions and ciliary localization,12,14,38–42 plasmids
encoding GFP-fused human miniCEP290580–1695,
miniCEP2901751–2050 and miniCEP2902037–2479 were
constructed (Fig. 1A). To test the functional potential
of the miniCEP290s, a surrogate assay system was
Figure 1. Generation of miniCEP290s. (A) Schematic representation of the full-length CEP290 protein depicts the location of the distinct protein interaction
domains. The regions used in generating the miniCEP290s are also indicated. MT, microtubule-binding domain. (B and C) The Cep290rd16 mouse embryonic
fibroblasts (MEFs) were transiently transfected with plasmids encoding GFP-fused full-length CEP290 or indicated miniCEP290s. The cells were then processed
for immunoblot analysis using protein extracts (50lg) analyzed by GFP antibody (B), or immunofluorescence analysis using GFP (green), ARL13B (red; ciliary
marker), and c-tubulin ( pink; basal body) antibodies (C). Scale bar: 10 lm. Nuclei were stained with DAP1 (blue). Arrows in (B) depict the GFP-CEP290
immunoreactive bands. Molecular weight markers are shown in kDa. Longer arrows in (C) indicate the CEP290-immunoreactive signal, whereas shorter arrows
depict cytoplasmic staining of the truncated CEP290. (D) Cilia length was quantified in the Cep290rd16 (green bars) or wild type (WT; red bars) MEFs expressing
GFP, GFP-CEP290-FL, or indicated miniCEP290s. *p < 0.01; ns, not significant. Color images available online at www.liebertpub.com/hum
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designed using Cep290rd16 MEFs. First, the expres-
sion and localization of the differentminiCEP290s in
the Cep290rd16 MEFs were investigated. The analy-
sis revealed that the FL CEP290 and all CEP290
domains expressed at comparable levels in theMEFs
(Fig. 1B). Additional bands observed in the immu-
noblot most likely represent degradation products
of the fusion protein. In addition to GFP-CEP290-
FL, miniCEP290580–1695 showed a predominant lo-
calization to the base of cilia (co-localization with
c-tubulin) and proximal cilia (co-localization with
ADP-Ribosylation Factor-Like 13B; ARL13B; cili-
ary marker; Fig. 1C). Other variants showed a rel-
atively diffuse pattern of localization. Next, the
ability of theminiCEP290s to modulate cilia length
in the Cep290rd16 MEFs was assessed. Cilia of
Cep290rd16 MEFs are around 1.7 lm in length
compared to controls, which have around 2.7 lm-
long cilia. Cilia length of theCep290rd16MEFswas
significantly increased when either FL GFP-
CEP290orGFP-miniCEP290580–1695was expressed.
Other variants and the plasmid expressing only
GFP did not change the cilia length. No effect
on the cilia length of the WT MEFs was observed
(Fig. 1D).
Next, it was asked whether further shorten-
ing of miniCEP290580–1695 would also result in a
cilia length rescue. To this end, plasmids encoding
GFP-miniCEP290580–1180 and miniCEP2901181–1695
were constructed. Both variants exhibited opti-
mal expression, as determined by immunoblot-
ting using GFP antibody (Fig. 2A). Additional
degraded products of the fusion protein were also
detected using the GFP antibody. While GFP-
miniCEP290580–1180 localized predominantly to
the cilia, miniCEP2901181–1695 exhibited a relatively
diffuse localization in the cytosol with some ciliary
localization (Fig. 2B). Cilia rescue assay showed that
expression of either variant resulted in a comparable
and significant increase in the cilia length of the
Cep290rd16 MEFs (Fig. 2C). Based on these results,
miniCEP290580–1180 and miniCEP2901181–1695 were
selected for further studies.
Effect of miniCEP290 injection on PR function
We cloned miniCEP290580–1180, mini
CEP2901181–1695, and miniCEP2902037–2479 (as
negative control) into AAV2 vector genome with
ubiquitously expressed CMVenhancer/CBA (chicken
b-actin) promoter containing the IRES between the
gene of interest and GFP. The IRES permits trans-
lation of CEP290 and GFP from a single bicistronic
mRNA, which assists in identifying the transduced
cells using GFP antibody. To assess the effect of
GFP expression, we also used AAV2-GFP expres-
sing construct as control. The viruseswere packaged
in AAV8 capsid, which is shown to transduce PRs
efficiently.43 The viruses were injected at 8·109 vg/
eye into the subretinal space of Cep290rd16 pups at
P0/P1. Similar doses have been successfully used to
treat retinal degeneration in mice.44 Injections at
higher doses resulted in toxicity (data not shown).
Figure 2. In vitro rescue potential of miniCEP290580–1180. (A) Protein extracts (50 lg) from Cep290rd16 MEFs transiently transfected with plasmids encoding
GFP, GFP-miniCEP290580–1180, or GFP-CEP2901181–1695 were analyzed by immunoblot analysis using GFP antibody. Arrows indicate GFP-miniCEP290 specific
immunoreactive bands. Molecular weight markers are shown in kDa. (B) Cep290rd16 MEFs expressing the indicated miniCEP290s were stained with GFP (green)
and ARL13B (red) antibodies. Nuclei were stained with DAPI (blue). Arrows indicate predominant localization of GFP signal at the proximal region of cilia.
Additional cytoplasmic staining of GFP was consistently detected in cells expressing GFP-miniCEP2901181–1695. Scale bar: 2lm. (C) Cilia length of WT or
Cep290rd16 MEFs expressing the indicated proteins was quantified. *p < 0.01. Color images available online at www.liebertpub.com/hum
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Analysis of PR function by ERG at 3 weeks
post injection revealed improvement (25–30%) in
both scotopic (rod PR-mediated) and photopic (cone
PR-mediated) responses of the miniCEP290580–1180-
injected mice (Fig. 3A–C). The miniCEP2901181–1695-
injectedmice revealed a relativelymild improvement
in the outer nuclear layer preservation (Supple-
mentary Fig. S1A and B; Supplementary Data are
available online at www.liebertpub.com/hum) and
scotopic and photopic ERG amplitudes (Supple-
mentary Fig. S1C and D). No improvement
was detected using miniCEP2902037–2479 or GFP
(Fig. 3). Age-matched uninjected mice were also
used as controls. Further analysis revealed that
the improvement in the ERG was stable up to
4 weeks and exhibited significantly decreased
amplitudes at 5 and 8 weeks post injection
(Fig. 3D). Although in vitro cilia length rescue
assay showed similar rescue effect with both
miniCEP290580–1180 and miniCEP2901181–1695
minigenes, the miniCEP290580–1180 is more potent
in vivo. Such results show that in vivo experiments
are important to validate the in vitro data, and
indicate the existence of domain-specific functions
of CEP290.
Effect of miniCEP290580–1180
on retinal morphology
To assess the effect of miniCEP290 injections on
retinal morphology, retinal cryosections were used
in which the injected regions were identified by
staining with GFP antibody. The number of layers
of the outer nuclear layer correlates with PR sur-
vival. The following were found: around six or
seven layers in the Cep290rd16 retinas injected
withminiCEP290580–1180 and two to three layers in
retinas injected with miniCEP2902037–2472 or GFP
(equivalent to uninjected Cep290rd16 at 3 weeks
of age; Fig. 4A). The number of layers in the outer
nuclear layer progressively declined with age
(Fig. 4B). Morphological analysis using ultrathin
sections of the Cep290rd16 retinas injected with
miniCEP290580–1180 exhibited significant preser-
vation of the outer nuclear layer at 3 weeks of age
(Fig. 4C).
Next, the structural preservation of the PR outer
segment was examined in the miniCEP290580–1180-
injected mice by staining with peripherin-RDS
(PR outer segment marker45). RDS is a structural
protein that specifically localizes to the outer seg-
ment discs and maintains the OS structure. The
miniCEP290580–1180-injected Cep290rd16 mice ex-
hibited improved RDS localization to the outer
segment compared to undetectable RDS expression
in the GFP-injected mice (Fig. 4D; red staining).
The expression of rhodopsin and cone opsins, two of
the key phototransduction proteins, was also ex-
amined. As predicted, there was undetectable opsin
expression in the miniCEP2902037–2479-injected ret-
inas. However, the miniCEP290580–1180-injected
retinas revealed detectable expression of rhodop-
sin and cone opsins in the outer segments (Fig. 5).
Some staining of cone opsins in the inner seg-
ment and outer nuclear layer was also observed.
Overall, the results suggest that the expression of
miniCEP290580–1180 can improve the function, mor-
phology, and opsin trafficking of the Cep290rd16
retinas.
DISCUSSION
Recent reports on the success of clinical trials of
gene therapy for RPE65-LCA and choroideremia
have provided considerable excitement in the field
of AAV-mediated gene delivery into the diseased
retina.28,30,46 However, progress in the develop-
ment of mutation-independent gene replacement
strategies for CEP290-LCA has been delayed lar-
gely because of unsuitability of the long CEP290
gene to be packaged into conventional AAV vector
system for gene therapy. This study reports the
generation and potential of a truncated CEP290
domain (miniCEP290580–1180) to mitigate associ-
ated retinal degeneration. The studies provide the
necessary first step to initiate the development of
miniCEP290 strategy for tackling associated reti-
nal ciliopathies, as well as systemic ciliopathies
due to CEP290 mutations.47 Taken together, evi-
dence is provided for slowing down of the severe
retinal degeneration using AAV-mediated delivery
of a CEP290 minigene.
Although the scotopic and photopic ERG am-
plitudes and PR survival improved in the
miniCEP290580–1180-treated retinas, they did not
reach the levels of the WT mice. Moreover, the im-
provement declined with age. Such observations
suggest that although the use ofminiCEP290580–1180
can be useful, additional analyses are needed to
generate a more potent miniCEP290 that can miti-
gate CEP290-associated retinal degeneration in a
diseased retina.
While themechanismofactionofminiCEP290580–1180
is currently unclear, the findings reveal the poten-
tial of the miniCEP290 to compensate partially for
the hypomorphic DCEP290 in the Cep290rd16
mouse.12 Although theDCEP290 protein carries the
domain encompassing 580–1180, the conformation
of the resultant protein may no longer be function-
ally active. Supplementing the Cep290rd16 retina
with aa 580–1180 likely provides the functional
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complementation needed to overcome the ciliary
defect. These observations suggest that the CEP290
protein is modular and demonstrates flexibility
in the protein structure–function relationship. This
is also evident from the associated diverse phe-
notypes associated with Cep290 mutant mice.
While the Cep290rd16 mice exhibit predominantly
retinal degenerative and other sensory defects, the
Cep290gt and Cep290ko mice manifest systemic dis-
orders.21–23,38 Additional investigations are neces-
sary to facilitate the generation of miniCEP290s
that can mitigate systemic CEP290-ciliopathies.
Nonetheless, the generation of partly functional PR
outer segments provides a stepping stone to develop
long-term disease correction when the therapy is
initiated after disease onset. Further studies will
focus on improving the efficacy of the miniCEP290s
to mitigate associated retinal ciliopathy.
This work provides a strategy to tackle the crit-
ical roadblock in designing a suitable gene thera-
peutic strategy for CEP290-LCA by developing
a mutation-independent approach. The relative
sparing of the central cone-rich region of the
CEP290-LCA patient retinas,25 such as in NPHP5-
LCA,48 suggests that gene therapy in this region can
be a viable option. However, there is dramatically
reduced cone function in patients. Further investi-
gations are needed to test the effect ofminiCEP290s
in dysfunctional CEP290-mutant cones, likely using
larger animalmodels (such as cat)24,49 and cone-rich
models.50
The use of minigenes as a therapeutic strategy
is a viable option for delivering large genes, as
has been demonstrated for dystrophin.32 Although
lentiviral and nanoparticle-based delivery strate-
gies for large genes, including ABCA4 (Stargardt
disease) and Usher Syndrome genes, are also being
investigated,51,52 the minigene approach offers a
relatively faster and translatable paradigm for
tackling such disorders.
Figure 4. In vivo morphological rescue potential of miniCEP290580–1180. Cep290rd16 retinas injected with indicated miniCEP290, GFP, or uninjected Cep290rd16 were
stained with DAPI (blue) (A). The outer nuclear layer (ONL) is marked with vertical lines. WT retinal section is shown for comparison. INL, inner nuclear layer. (B)
Quantification of the ONL thickness by counting the number of layers of the vector transduced region of the injected Cep290rd16 mice compared to uninjected
retinas is represented. There is initial preservation of the number of layers, but progressive decline is detected with age. ***p< 0.0001. (C) The injected Cep290rd16
mouse retinas were also examined by ultrathin sectioning to assess morphological preservation at 3 weeks post injection. The ONL is marked with vertical lines.
The outer segment (OS) layer is clearly visible in the miniCEP290580–1180 injected retinas. (D) Improved expression of RDS (red) is detected in the miniCEP290580–1180
injected Cep290rd16 mice. Staining with GFP (green) marked the injected regions. Color images available online at www.liebertpub.com/hum
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Figure 5. Opsin trafficking in miniCEP290580–1180-injected retinas. Retinal cryosections of Cep290rd16 mice injected with the indicated miniCEP290s were
stained with GFP (injected regions; green), rhodopsin (RHO; purple; rod-specific; A), or M-opsin (MOP; red; cone-specific; B) antibodies and DAPI (blue; nuclei).
OS-enriched opsin staining is detected in the miniCEP290580–1180-injected retinas. Dramatically reduced expression of opsins is detected in the miniCEP2902037–
2479-injected retinas. GCL, ganglion cell layer. Color images available online at www.liebertpub.com/hum
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